Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, November 27, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
  Videos

Return

Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
SelectBio

The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance. In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Big Data Set To Make A Big Difference In Childhood Cancer Treatment
UTS researchers are working with the Kids Research Institute to visualise large quantities of patient data to better diagnose and treat childhood cancer patients.
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
Fast, Low-cost DNA Sequencing Technology One Step Closer To Reality
ASU Regents' Professor Stuart Lindsay led a team of scientists from Arizona State University's Biodesign Institute and IBM's T.J. Watson Research Center in the development of a prototype DNA reader that could make whole genome profiling an everyday practice in medicine.
Developing a Noninvasive Test for Endometriosis
UCSF researchers identify patterns of genetic activity that could help in early detection of disorder.
Breakthrough in Managing Yellow Fever Disease
UC Riverside-led research could lead to antiviral therapeutics and better diagnostics to prevent spread of potentially fatal viral infection.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Blood Test Could Reduce Antibiotic Use
A new blood biomarker test that indicates whether bacteria is the cause of a patient’s lung infection is now being studied at UPMC Presbyterian.
Light Shed On Genetic Architecture Of Kidney Cancer
Research reveals link between renal cell carcinoma and exposure to aristolochic acid.
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
Typhoid Gene Unravelled
Natural resistance against typhoid fever is linked to a particular form of the HLA-DRB1 gene.
Scroll Up
Scroll Down
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv